Literature DB >> 15784715

Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.

Neville H Golden1, Elba A Iglesias, Marc S Jacobson, Dennis Carey, Wendy Meyer, Janet Schebendach, Stanley Hertz, I Ronald Shenker.   

Abstract

Osteopenia is a serious medical complication of anorexia nervosa, with no known effective treatment. We conducted a double-blinded, randomized trial comparing alendronate (10 mg daily) with placebo in 32 adolescents with anorexia nervosa (mean age, 16.9 +/- 1.9 yr). All subjects received 1200 mg elemental calcium and 400 IU vitamin D daily and received the same multidisciplinary treatment for their eating disorder. Bone mineral densities (BMDs) of the lumbar spine and femoral neck were measured by dual energy x-ray absorptiometry at baseline and after 1 yr of treatment. Twenty-nine subjects completed the study. Femoral neck and lumbar spine BMDs increased 4.4 +/- 6.4% and 3.5 +/- 4.6% in the alendronate group compared with increases of 2.3 +/- 6.9% and 2.2 + 6.1% in the control group (P = 0.41, femoral neck; P = 0.53, lumbar spine). From baseline to follow-up, BMD increased significantly at the femoral neck (P = 0.02) and lumbar spine (P = 0.02) in those receiving alendronate, but did not increase in those assigned placebo (P = 0.22, femoral neck; P = 0.18, lumbar spine). At follow-up, body weight was the most important determinant of BMD. BMD was significantly higher in subjects who were weight-restored compared with those who remained at low weight (P = 0.002, femoral neck; P = 0.04, lumbar spine). After controlling for body weight, treatment group assignment still had an independent effect at the femoral neck. We conclude that in adolescents with anorexia nervosa, weight restoration is the most important determinant of BMD, but treatment with alendronate did increase the BMD of the lumbar spine and femoral neck within the group receiving alendronate, but not compared with placebo in the primary analysis. Until additional studies have demonstrated efficacy and long-term safety, the use of alendronate in this population should be confined to controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784715     DOI: 10.1210/jc.2004-1659

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  62 in total

1.  Optimizing bone health in anorexia nervosa and hypothalamic amenorrhea: new trials and tribulations.

Authors:  Joo-Pin Foo; Ole-Petter R Hamnvik; Christos S Mantzoros
Journal:  Metabolism       Date:  2012-01-31       Impact factor: 8.694

Review 2.  Effects of hypogonadism on bone metabolism in female adolescents and young adults.

Authors:  Madhusmita Misra
Journal:  Nat Rev Endocrinol       Date:  2012-01-24       Impact factor: 43.330

Review 3.  State of the art systematic review of bone disease in anorexia nervosa.

Authors:  Madhusmita Misra; Neville H Golden; Debra K Katzman
Journal:  Int J Eat Disord       Date:  2015-08-27       Impact factor: 4.861

Review 4.  Premenopausal bone health: osteoporosis in premenopausal women.

Authors:  Alice Abraham; Adi Cohen; Elizabeth Shane
Journal:  Clin Obstet Gynecol       Date:  2013-12       Impact factor: 2.190

5.  The female athlete triad: a case series and narrative overview.

Authors:  Michelle A Laframboise; Cameron Borody; Paula Stern
Journal:  J Can Chiropr Assoc       Date:  2013-12

Review 6.  Underweight, overweight, and pediatric bone fragility: impact and management.

Authors:  Shara R Bialo; Catherine M Gordon
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

Review 7.  The neuroendocrine basis of anorexia nervosa and its impact on bone metabolism.

Authors:  Madhusmita Misra; Anne Klibanski
Journal:  Neuroendocrinology       Date:  2011-01-13       Impact factor: 4.914

Review 8.  The endocrine manifestations of anorexia nervosa: mechanisms and management.

Authors:  Melanie Schorr; Karen K Miller
Journal:  Nat Rev Endocrinol       Date:  2016-11-04       Impact factor: 43.330

9.  Evaluation and management of the premenopausal woman with low BMD.

Authors:  Adi Cohen; Elizabeth Shane
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

10.  Bone mineral density in partially recovered early onset anorexic patients - a follow-up investigation.

Authors:  Ulrike Me Schulze; Simone Schuler; Dieter Schlamp; Peter Schneider; Claudia Mehler-Wex
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2010-07-08       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.